Design of a cost-effectiveness study within a randomized trial: The LIPID trial for secondary prevention of IHD

Controlled Clinical Trials

Volumn 18, Issue 5, 1997, Pages 464-476

  Glasziou, Paul P ^a   Simes, R John ^b   Hall, Jane ^c   Donaldson, Cam ^d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Clinical trial; Cost effectiveness; Quality of life (QOL)

Indexed keywords

PLACEBO; PRAVASTATIN;

ARTICLE; AUSTRALIA AND NEW ZEALAND; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HUMAN; INFORMATION PROCESSING; INTERVIEW; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAMPLE; SECONDARY PREVENTION; SURVIVAL; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

ABSENTEEISM; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; AUSTRALIA; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; HEALTH RESOURCES; HUMANS; MYOCARDIAL INFARCTION; NEW ZEALAND; PRAVASTATIN; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 0031446174     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(97)00011-1     Document Type: Article

References (26)

1. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
2. Peto R, Yusuf S, and Collins R. Cholesterol-lowering trial results in their epidemiological context. Circulation 1985;72(suppl):451S.
3. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients from Australia and New Zealand with previous myocardial infarction and/or unstable angina. Am J Cardiol (under revision).
4. Saito Y, Goto Y, Nakaya et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects: a double-blind test. Atherosclerosis 1988;72:205-211.
5. Walker S, Shaw J, Ritchie J et al, eds. Heart Health Resource Manual. Sydney: National Heart Foundation of Australia (NSW Division); 1988.
6. Evans D, Freund D, Dittus R, Robertson J, Henry D. Background Document on the Use of Economic Analysis as a Basis for Inclusion of Pharmaceutical Products on the Pharmaceutical Benefits Scheme. Canberra: Commonwelath Government Printer; 1993.
7. Commonwealth of Australia. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Major Submissions Involving Economic Analyses. Canberra: Australian Government Publishing Service;1995:1-78.
8. Province of Ontario. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health;1994.
9. Gross PF, Glasziou PP, Donaldson C. The Cost-Effectiveness of Treating Mild Hypertension with ACE Inhibitors and Beta-blockers. Sydney: Institute of Health Economics and Technology Assessment;1989.
10. Kinosian BP, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-2254.
11. Gudex C, Kind P. The QALY Toolkit: Discussion Paper Number 38. York: York Centre for Health Economics, University of York; 1988.
12. Torrance GW. Measuring health state utilities for economic evaluation. Health Econ 1986;5:1-30.
13. Glasziou PP, Bromwich S, Simes RJ for the AUS-TASK Group. Quality of life 6 months after myocardial infarction. Med J Aust 1994;161:532-535.
14. Scheaffer RL, Mendenhall W, Ott L. Elementary Survey Sampling 3rd ed. Boston: Duxbury Press; 1986.
15. McNeil B, Weichselbaum R, Pauker S. Fallacy of the five-year survival in lung cancer. N Eng J Med 1978;299:1397-1401.
16. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use. New York: Oxford Medical Publication; 1989.
17. Commonwealth of Australia. Manual of Resource Items and Their Associated Costs. Canberra: Australian Government Publishing Service; 1992.
18. Drummond M, Stoddard G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Press; 1989.
19. Commonwealth of Australia. Medicare Benefits Schedule Book. Canberra: Australian Government Publishing Service; 1995.
20. Palmer G, Aisbett C, Fetter R, Winchester L, Reid B, Rigby E. Casemix Costs and Casemix Accounting in Seven Major Sydney Teaching Hospitals. Sydney: Centre for Hospital Management and Information Systems Research; 1991.
21. Commonwealth Department of Human Services and Health. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra; published quarterly.
22. Glasziou PP, Simes RJ, Gelber R. Quality Adjusted Survival Analysis. Stat Med 1990;9:1259-1276.
23. Puma J, Lawlor EF. Quality-Adjusted Life-Years. JAMA 1990:2917-2921.
24. Harris J. QALYfying the value of life. J Med Ethics 1987;13:117-123.
25. Carr-Hill RA, Morris J. Current practice in obtaining the "Q" in QALYs: a cautionary note. Brit Med J 1991;303:699-701.
26. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London: Chapman & Hall; 1993.